[
    [
        {
            "time": "",
            "original_text": "天坛生物：公司国内市场的主要销售模式是将产品通过配送商销往各级医疗机构和零售药店等终端客户",
            "features": {
                "keywords": [
                    "天坛生物",
                    "销售模式",
                    "配送商",
                    "医疗机构",
                    "零售药店"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "天坛生物：公司国内市场的主要销售模式是将产品通过配送商销往各级医疗机构和零售药店等终端客户",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "天坛生物：目前永安血制项目尚未正式投产",
            "features": {
                "keywords": [
                    "天坛生物",
                    "永安血制",
                    "未投产"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "天坛生物：目前永安血制项目尚未正式投产",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "天坛生物：“静注COVID-19人免疫球蛋白（pH4）”尚需完成临床试验等，预计短期内无法形成销售收入",
            "features": {
                "keywords": [
                    "天坛生物",
                    "静注COVID-19人免疫球蛋白",
                    "临床试验",
                    "短期",
                    "无收入"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "天坛生物：“静注COVID-19人免疫球蛋白（pH4）”尚需完成临床试验等，预计短期内无法形成销售收入",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "天坛生物：公司所属成都蓉生药业有限责任公司已获得“人凝血因子Ⅷ”的药品注册证书，并已通过GMP符合性检查，可进行该产品的生产、上市和销售",
            "features": {
                "keywords": [
                    "天坛生物",
                    "成都蓉生",
                    "人凝血因子Ⅷ",
                    "药品注册证书",
                    "GMP符合性检查",
                    "生产",
                    "上市",
                    "销售"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天坛生物：公司所属成都蓉生药业有限责任公司已获得“人凝血因子Ⅷ”的药品注册证书，并已通过GMP符合性检查，可进行该产品的生产、上市和销售",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        }
    ]
]